Systemic psoriasis treatments showing huge growth

[Fred]

New research published by Research And Markets shows Market value of Systemic psoriasis treatments are set to rise from $5 billion in 2013 to $10.4 billion by 2020.

Quote:

---

The systemic psoriasis treatment market value in the eight major countries (8MM) — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — is expected to more than double in the near future, jumping from $5 billion in 2013 to $10.4 billion by 2020, at a significant Compound Annual Growth Rate (CAGR) of 11.1%

The company’s new report states that across the 8MM, 4.1 million people were diagnosed with some form of moderate-to-severe psoriasis in 2013. This number is expected to climb slightly to 4.4 million by 2020, with 1.5 million of the population being treated with systemic agents.

Fiona Chisholm, report analyst, says: “This growth in the treatment population will be driven by a marginal rise in the global prevalence of psoriasis, as well as an increase in the diagnosis rate resulting from higher disease awareness and improved diagnostic methods.

“Additionally, psoriasis is increasingly being recognized as a serious systemic disease with associated quality of life impairment and disability, rather than as a simply cutaneous disease. As perceptions of psoriasis continue to change, healthcare professionals will consider treatment as non-optional.”

Although some revenue losses are anticipated to occur throughout the forecast period, due to patent expiries, the introduction of new, novel biologics with positive efficacy profiles will drive further market growth.

According to the authors, secukinumab, brodalumab and ixekizumab are three particularly promising, late-stage pipeline monoclonal antibodies directly targeting IL–17, a pro-inflammatory cytokine. In addition to these upcoming biologics, some orally administered, small molecule compounds are also expected to enter the market over the coming years, such as Xeljanz, a janus kinase inhibitor, and apremilast, a PDE4 inhibitor.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.

Source: NO LINKS ALLOWED